Objective-To determine the cardiac, renal, and neuroendocrine effects of lisinopril in men with untreated, symptom free left ventricular systolic dysfunction. Design-A randomised, double blind cross over trial with six week treatment periods to compare lisinopril (10 mg/day) and matching placebo.
Patients with ventricular dysfunction that has progressed to overt heart failure have a poor prognosis. Even in those with very mild heart failure about 50% will die within five years.1 2 Preservation of ventricular function and prevention of progression to overt heart failure are important goals in the management of symptom free ventricular dysfunction that are likely to improve prognosis.
The Studies of Left Ventricular Dysfunction showed that enalapril can delay or prevent the onset of heart failure in patients with compromised left ventricular function,3 and slow the deterioration in the patients' condition thereafter, thereby reducing mortality. These studies, however, have not generally considered the mechanisms by which such benefits were derived.
Previous studies have indicated that the renin angiotensin aldosterone system is not significantly activated in patients with ventricular dysfunction untreated by diuretics, which might suggest that such patients would have little to gain from an angiotensin converting enzyme inhibitor. 4 Evidence from studies with animals, however, suggests that although the RAA system activity seems normal in untreated ventricular dysfunction it may be tonically suppressed by subclinical salt and water retention rather than merely not activated. 5 The aims of our study were to investigate the effects of the ACE inhibitor lisinopril on cardiac, neuroendocrine and renal function in a group of patients with considerably impaired ventricular function due to ischaemic heart disease.
Patients and methods Eighteen men, mean (SD) age 58 (7) years with minimal or no symptoms of heart failure but with echocardiographic evidence of considerable left ventricular dysfunction were identified. Before the screening visit for inclusion in the study, one patient died unexpectedly during sleep. The mean (SD) left ventricular ejection fraction measured by radionuclide ventriculography was 39-9% (10-2%) at baseline in the remaining 17 patients who started the study. Ejection fraction in eight age and sex matched control patients who had had a coronary bypass but who had no evidence of myocardial infarction or ventricular dysfunction was 66-0% (7.9%).
All patients had had a previous myocardial infarction that had affected the anterior (10), inferior (three), or both territories (four). No patient had had a myocardial infarction within one year of the study. Eleven had had coronary revascularisation, but none within six months of the study. The Variables were first tested for order or period effects; if such effects had been found, that variable would have been excluded from further statistical analysis. This was not necessary. The changes from baseline to the end of each treatment phase were compared. Student's t test was used with prior logarithmic transformation of the data if they were not normally distributed.
Two patients were randomised but failed to complete the study (explained later). Neither outcome was thought to have influenced the outcome in favour of active treatment.
Results
CLINICAL OUTCOME Fifteen patients completed the study. One patient decided not to participate further after completing the baseline tests, but before receiving any study medication. One patient completed the first six weeks of the study receiving lisinopril and improved his exercise performance, but developed dizziness while receiving placebo, stopped treatment some days before the two week visit, and was excluded from analysis.
No patient developed symptomatic hypotension after the first dose of lisinopril. All patients progressed to the higher dose of lisinopril. Tables 1 and 2 show that despite the lack of symptoms, exercise performance was impaired. Plasma concentrations of atrial natriuretic peptide were increased above the laboratory range but those of active renin, angiotensin II, aldosterone, and noradrenaline were not. Renal blood flow and glomerular filtration rate were well preserved.
BASELINE STUDY RESULTS

EFFECTS OF LISINOPRIL
Heart rate and blood pressure Lisinopril did not affect lying or standing blood pressure at rest or resting heart rate ( was breathlessness.
Neuroendocrine function Treatment with lisinopril (10 mg) once daily resulted in a decline in the plasma concentrations of angiotensin II, aldosterone, and atrial natriuretic peptide, whereas plasma concentrations of active renin rose (table 3) .
Serum electrolytes, urea, and creatinine No change in haematological or biochemical variables was found.
Discussion
The SOLVD study recently reported that enalapril could delay or prevent symptom free patients with impaired left ventricular function from developing overt heart failure.3 How ACE inhibitors induce such benefit is poorly understood.
HAEMODYNAMIC EFFECTS
Inhibitors of ACE could improve prognosis by improving left ventricular function.9 In the Second Veterans Administration Heart Failure Trial (V-HeFT II) study, however, ejection fraction and exercise performance were improved to a greater extent by conventional vasodilators and yet enalapril exerted a greater benefit on prognosis. 4 In our study lisinopril did not improve reduced resting left ventricular function, but did improve impaired maximum exercise capacity as assessed by peak oxygen consumption. Most people rarely exercise to their cardiorespiratory maximum, so it is not surprising that cardiac reserve was considerably reduced despite the lack of symptoms. High intensity protocols are known to produce greater cardiopulmonary stress and be limited more specifically by breathlessness. Patients subjected to low intensity protocols stop exercising for more varied reasons'0 that are probably more closely related to the peripheral circulation and skeletal muscle conditioning.
Dickstein et al recently reported that enalapril did not improve impaired exercise performance in patients after a myocardial infarction," but all the patients in that study were taking f blockers. Patients with evidence of reversible ischaemia, which may be exacerbated by ACE inhibitors,'2 were excluded from both studies.
By improving cardiac reserve, ACE inhibitors may not only pull the patient back from the threshold at which heart failure would have occurred, but also slow the rate of deterioration in ventricular function, and prevent heart failure appearing during further acute insults such as atrial fibrillation.
NEUROENDOCRINE EFFECTS
Activation of neuroendocrine systems individually or in combination is associated with a worse prognosis, and may contribute directly to the progression of ventricular dysfunction. Intense activation identifies a group of patients who seem to have more to gain prognostically by treatment with an ACE inhibitor."3 14 However, in clinically stable patients with ventricular dysfunction, which is untreated by diuretics, studies suggest that only atrial natriuretic peptide is increased before the onset of heart failure. 
